Simultaneous use of the drug Augmentin® CP and probenecid are not recommended. Probenecid reduces the tubular secretion of amoxicillin, and therefore the simultaneous use of the drug Augmentin® CP and probenecid can lead to an increase and persistence in the blood concentration of amoxicillin, but not clavulanic acid.
Concomitant use of allopurinol and amoxicillin may increase the risk of skin allergic reactions. Currently, there is no data in the literature on the simultaneous use of a combination of amoxicillin with clavulanic acid and allopurinol.
Penicillins are able to slow the elimination of methotrexate from the body by inhibiting its tubular secretion, so the simultaneous use of the drug Augmentin® CP and methotrexate may increase the toxicity of methotrexate.
Like other antibacterial drugs, the drug Augmentin® CP can affect the intestinal microflora, leading to a decrease in the absorption of estrogens from the gastrointestinal tract and a decrease in the effectiveness of combined oral contraceptives.
The literature describes rare cases of increased MHO in patients with the combined use of acenocumarol or warfarin and amoxicillin. If necessary, simultaneous administration or withdrawal of the drug Augmentin® CP with PV or MHO anticoagulants should be carefully monitored, and the dose of anticoagulants for oral administration may need to be adjusted.
According to the recipe.
Before starting treatment with Augmentin® SR it is necessary to collect a detailed history of previous hypersensitivity reactions to penicillins, cephalosporins.
Serious and sometimes fatal hypersensitivity reactions (anaphylactic reactions) to penicillins have been described. The risk of such reactions is highest in patients with a history of hypersensitivity reactions to penicillins. In the event of an allergic reaction, it is necessary to stop treatment with Augmentin® CP and start appropriate alternative therapy.
In case of serious anaphylactic reactions, epinephrine should be administered immediately to the patient. Oxygen therapy, intravenous administration of corticosteroids, and airway patency, including intubation, may also be required.
In case of suspected infectious mononucleosis, the drug Augmentin® CP should not be used, because in patients with this disease, amoxicillin can cause a bark-like skin rash, which makes it difficult to diagnose the disease.
Long-term treatment with Augmentin® CP sometimes leads to an excessive multiplication of insensitive microorganisms.
In order to reduce the risk of side effects from the gastrointestinal tract, you should take the drug at the beginning of a meal.
In patients treated with a combination of amoxicillin and clavulanic acid together with indirect (oral) anticoagulants, an increase in PV (an increase in MHO) was rarely reported. When co-prescribing indirect (oral) anticoagulants with a combination of amoxicillin and clavulanic acid, monitoring of the corresponding indicators is necessary. To maintain the desired effect of oral anticoagulants, it may be necessary to adjust their dose.
No dose adjustment is required for Augmentin® CP for patients with creatinine Cl ≥30 ml/min. It is not recommended to prescribe the drug to patients with creatinine Cl <30 ml/min. In patients with reduced diuresis, the development of crystalluria has been reported in very rare cases, mainly with parenteral use of the drug. When taking high doses of amoxicillin, it is recommended to take a sufficient amount of fluid and maintain adequate diuresis to reduce the likelihood of amoxicillin crystals forming (see "Overdose").
Taking the drug Augmentin® Oral CP leads to a high content of amoxicillin in the urine, which can lead to false positive results when determining glucose in the urine (for example, the Benedict test, the Fehling test). In this case, it is recommended to use a glucose oxidant method for determining the concentration of glucose in the urine.
Abuse and drug addiction. Drug dependence, addiction, and euphoric reactions associated with the use of the drug Augmentin were not observed® WED.
Influence on the ability to drive vehicles and work with mechanisms. Since the drug can cause dizziness, it is necessary to warn patients about precautions when driving a vehicle or working with moving mechanisms.
At a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life of the drug Augmentin® WED2 года.Do not use after the expiration date indicated on the package.
| Modified-release film-coated tablets | 1 table. |
| An immediate release layer | |
| active ingredients: | |
| amoxicillin trihydrate | 654.1 mg |
| (equivalent to 562.5 mg of amoxicillin) | |
| potassium clavulanate | 76.2 mg |
| (equivalent to 62.5 mg of clavulanic acid) | |
| excipients: MCC — 136.4 mg, sodium carboxymethyl starch-18 mg, colloidal anhydrous silicon dioxide-6.3 mg, magnesium stearate-9 mg | |
| A layer that provides gradual release | |
| active substance: | |
| amoxicillin sodium | 480.8 mg |
| (equivalent to 437.5 mg of amoxicillin) | |
| excipients: MCC — 111.7 mg, xanthan gum-14 mg, citric acid-78 mg, colloidal anhydrous silicon dioxide-1.5 mg, magnesium stearate-14 mg | |
| Water film shell: hypromellose 6 cps-11.6 mg, hypromellose 15 cps-3.9 mg, titanium dioxide-15.1 mg, macrogol 3350-2.3 mg, macrogol 8000 — 2.3 mg |
Modified release film-coated tablets, 1000 mg 62.5 mg. In a blister made of PVC or PE / aluminum foil, 2 pcs. 2 blisters in a combined package with a dividing line between them. 4, 7 or 10 combined packages in a pack of cardboard.
J01CR02 Amoxicillin in combination with a beta-lactamase inhibitor
